Atasin 40 Tab (Atorvastatin) – ACI Limited

1. About Atasin 40 Tab (Atorvastatin Calcium)

Atasin 40 Tab contains Atorvastatin Calcium 40 mg, a high-intensity HMG-CoA reductase inhibitor manufactured by ACI Limited, Bangladesh. The 40 mg dose provides approximately 46–51% reduction in LDL-cholesterol — defined as high-intensity statin therapy by ACC/AHA 2018 guidelines. It is the standard dose for secondary cardiovascular prevention, high-risk T2DM patients, and familial hypercholesterolaemia.

ACI Limited's Atasin range covers all four clinically relevant atorvastatin doses (10, 20, 40, 80 mg), allowing clinicians to titrate from starting doses to high-intensity therapy within a single trusted brand. Atasin 40 Tab is the high-intensity formulation most commonly prescribed for post-MI, post-ACS, and T2DM + established CVD patients in Bangladeshi cardiology and endocrinology practice.

2. Mechanism of Action

Atorvastatin 40 mg competitively inhibits HMG-CoA reductase at near-maximal clinical effect. The result: (1) dramatically reduced hepatic cholesterol synthesis; (2) upregulated LDL receptors on hepatocytes → enhanced LDL-C clearance from circulation; (3) reduced VLDL production → lower triglycerides; (4) modest HDL-C elevation. The logarithmic dose-response means 40 mg achieves ~46–51% LDL reduction vs ~30–35% at 10 mg — each dose doubling adds ~6% additional LDL-C reduction.

Active metabolites (2-OH and 4-OH atorvastatin) extend the effective inhibitory half-life to 20–30 hours. Pleiotropic benefits include reduced CRP, improved endothelial function, plaque stabilisation, and reduced thrombogenicity.

3. Indications

• Post-MI, post-ACS secondary prevention (high-intensity therapy is standard of care)
• Established stable coronary artery disease, peripheral arterial disease
• Prior ischaemic stroke/TIA prevention
• Very-high-risk T2DM: DM + established CVD or DM + CKD or DM + ≥3 major CV risk factors
• Familial hypercholesterolaemia — high-intensity mandatory
• Primary prevention at very high 10-year CVD risk (>20%)

4. Dosage and Administration

40 mg once daily, any time of day, with or without food. Long half-life (~14h parent; ~20–30h active metabolites) ensures 24-hour HMG-CoA inhibition. Reassess LDL-C at 6–8 weeks. If very-high-risk LDL target (<1.4 mmol/L) not met, add ezetimibe 10 mg or escalate to atorvastatin 80 mg. No dose adjustment for renal impairment.

5. Contraindications

• Active liver disease / persistently elevated transaminases (>3× ULN)
• Pregnancy (teratogenic — Category X) and breastfeeding
• Hypersensitivity to atorvastatin or excipients

6. Warnings and Precautions

Myopathy/Rhabdomyolysis: Dose-dependent risk — higher at 40 mg than lower doses. Absolute incidence low but significant with interacting drugs (cyclosporine contraindicated; strong CYP3A4 inhibitors — reduce dose; gemfibrozil — avoid). Monitor CK if symptomatic. IMNM: rare serious immune-mediated myopathy — check anti-HMGCR antibodies; requires immunosuppression.

Liver: Baseline LFTs; recheck if symptomatic. ALT >3× ULN on 2 measurements: reduce dose or stop.

Drug interactions at 40 mg are critical — always check concurrent medications before prescribing.

7. Side Effects

Common: Myalgia (dose-dependent), arthralgia, headache, nasopharyngitis, GI symptoms, insomnia, elevated CK.

Uncommon: Elevated transaminases, peripheral neuropathy, alopecia, cognitive effects.

Rare: Rhabdomyolysis, IMNM, hepatitis, angioedema, pancreatitis, lupus-like syndrome.

8. Key Drug Interactions at 40 mg

• Cyclosporine: Contraindicated at 40 mg — max 10 mg atorvastatin
• Clarithromycin, itraconazole, HIV PIs: Significantly raise atorvastatin levels — limit to 20 mg
• Gemfibrozil: Avoid — myopathy risk; use fenofibrate if fibrate needed
• Warfarin: Monitor INR
• Colchicine: Caution — additive myopathy

9. Storage

• Below 30°C, cool dry place, protected from light. Original blister. Out of reach of children.

Frequently Asked Questions (FAQ)

Q1: Is Atasin 40 Tab the same as Atasin 40 mg Tablet?

Yes — Atasin 40 Tab and Atasin 40 mg Tablet are the same medication: Atorvastatin Calcium 40 mg by ACI Limited, Bangladesh. Both contain the identical active ingredient at the same strength, manufactured by the same company to the same GMP standards. The name variation ("Tab" vs "Tablet") reflects different product listings but the clinical product is identical — 40 mg atorvastatin, high-intensity statin therapy, for the same indications (post-MI, established ASCVD, very-high-risk T2DM, FH).

Q2: How does Atasin 40 Tab help T2DM patients?

T2DM is a major cardiovascular risk factor — T2DM patients have 2–4× higher cardiovascular risk than non-diabetics. Atasin 40 Tab (Atorvastatin 40 mg) provides high-intensity LDL-C reduction (~46–51%) in T2DM patients with established CVD or multiple CV risk factors. Per ADA and BDEA guidelines: all T2DM aged ≥40 with additional risk factors should receive high-intensity statin (atorvastatin 40 mg or equivalent). The CARDS trial established atorvastatin's 37% CVD event reduction in T2DM — higher doses achieve greater LDL targets. Atasin 40 Tab helps T2DM patients reach the aggressive LDL targets (<1.8–1.4 mmol/L) required for high and very-high-risk T2DM.

Q3: Can Atasin 40 Tab be used during Ramadan fasting?

Yes — atorvastatin can be safely taken during Ramadan fasting. Its long half-life means once-daily dosing is equally effective whether taken at Suhoor (pre-dawn), during the day (by non-fasting patients), or at Iftar (sunset). Fasting does not significantly alter atorvastatin absorption or efficacy. Many Bangladeshi patients take their evening medications at Iftar — Atasin 40 Tab can follow this pattern without any dose adjustment. Maintaining consistent daily dosing during Ramadan is more important than the specific timing.

Q4: What monitoring is required for Atasin 40 Tab?

Recommended monitoring for Atasin 40 Tab (high-intensity atorvastatin): (1) Lipid profile (LDL-C): Baseline before starting; recheck at 6–8 weeks to assess response and guide titration; then every 6–12 months once target achieved. (2) Liver function tests (LFTs): Baseline before starting; recheck if symptomatic (jaundice, abdominal pain, fatigue). Routine periodic monitoring not mandated by current guidelines unless symptomatic. (3) CK levels: Check if myalgia or muscle weakness develops — not required routinely. (4) Blood glucose (HbA1c): High-dose statins modestly increase glucose — monitor in at-risk patients. Report any unexplained muscle pain, weakness, or dark urine to your physician immediately.